Australia's PBAC considers 'a' flagging biosimilars, and listing of first biosimilar insulin

The Australian Generic Medicines Industry Association (GMiA) says it welcomes the decision of the Pharmaceutical Benefits Advisory Committee (PBAC) to consider “a” flagging of biosimilars, and to list biosimilar insulin (Basaglar) on the Pharmaceutical Benefits Scheme (PBS).

The decision to apply an “a” flag to a biosimilar in the Schedule of Pharmaceutical Benefits will enable a pharmacist to substitute the biosimilar for the reference biological medicine in exactly the same way as generic medicines.

Biosimilar of Sanofi’s Lantus